Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivative

Grasso G., Sfacteria A., Erbayraktar S., Passalacqua M., Meli F., Gokmen N., ...Daha Fazla

JOURNAL OF NEUROSURGERY-SPINE, cilt.4, sa.4, ss.310-318, 2006 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 4 Sayı: 4
  • Basım Tarihi: 2006
  • Doi Numarası: 10.3171/spi.2006.4.4.310
  • Dergi Adı: JOURNAL OF NEUROSURGERY-SPINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.310-318
  • Anahtar Kelimeler: erythropoietin, neuroprotection, spinal cord injury, rat, RECOMBINANT-HUMAN-ERYTHROPOIETIN, GLYCOGEN-SYNTHASE KINASE-3-BETA, CENTRAL-NERVOUS-SYSTEM, ATTENUATES PROGRESSIVE NECROSIS, ISCHEMIA-REPERFUSION INJURY, GLOBAL CEREBRAL-ISCHEMIA, IN-VIVO, MEDIATED NEUROPROTECTION, SUBARACHNOID HEMORRHAGE, NEUROLOGICAL RECOVERY
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Object. Spinal cord injury (SCI) is a devastating clinical syndrome for which no truly efficacious therapy has yet been identified. In preclinical studies, erythropoietin (EPO) and its nonerythropoietic derivatives asialoEPO and carbamylated EPO have markedly improved functional outcome when administered after compressive SCI. However, an optimum treatment paradigm is currently unknown. Because the uninjured spinal cord expresses a high density of EPO receptor (EPOR) in the basal state, signaling through these existing receptors in advance of injury (pharmacological preconditioning) might confer neuroprotection and therefore be potentially useful in situations of anticipated damage.